Connect with us

NEWS

Elomia Health Buys Earkick to Sell Wellbeing as Infrastructure

Elomia Health bought Earkick for its models and Mia21 memory access, packing a consumer companion into a hospital wellbeing API.

Published

on

Elomia Health said on November 10, 2026 that it had acquired Earkick, an AI companion used by more than 250,000 people. The buyer takes Earkick’s models and ongoing early access to Mia21, a memory engine, as it sells a wellbeing API to hospitals, employers and universities.

Price was not disclosed. The Earkick consumer app’s future was not either. What the companies named in public are models, memory and a safety layer meant for other organisations’ chatbots.

A Ukrainian Lab Bought a Companion Used by 250,000 People

Taras Pohrebniak, a Ukrainian entrepreneur, founded Elomia Health in 2019 as a lab for large language models in wellbeing. The firm ran its own consumer app, then moved toward an API that care groups can embed. Dr. Herbert Bay, co-inventor of the 2006 SURF detector and descriptor, founded Earkick in 2021 with Karin Andrea Stephan, whose work on everyday emotional support shaped the product. People use it to vent and to track mood, sleep, activity and daily habits, then get suggestions tied to that log.

WHAT EACH SIDE BROUGHT

Piece Elomia Health Earkick
Started 2019, Pohrebniak 2021, Bay and Stephan
Public scale Consumer app, now an API More than 250,000 people
Named tech Models plus a safety and overreliance layer Companion models plus Mia21 memory
What moved Buyer Models, and early access to new Mia21 versions

Bay said the mission from the start was to make mental wellbeing more measurable, personal and accessible. He called Pohrebniak one of the first to bring large language models into the wellbeing field, and said the two firms together could build something stronger than either could alone. Stephan, Earkick’s chief operating officer, said bringing the companies together takes personalised support closer to scale. She has also argued that a well-timed message, grounded in a person’s own data, can save lives.

The Swiss Company Went Into Liquidation in March

Earkick listed San Francisco and Zurich. The Swiss limited company behind the name was already winding down when Elomia spoke. Earkick GmbH sat in Wädenswil, on Meierhofstrasse 23, with share capital of 20,000 Swiss francs and register number CHE-358.783.088. On March 24, 2026, 231 days before the acquisition notice, shareholders dissolved the company in March and put Stephan in as liquidator with a sole signature.

THE WADENSWIL REGISTER FILE

  1. October 26, 2021: Earkick GmbH is entered at the Zurich commercial registry as a limited company in IT services.
  2. September 3, 2024: Stephan leaves dual-signature management and Bay becomes sole signatory.
  3. March 24, 2026: Shareholders vote to dissolve the company.
  4. April 22, 2026: The firm is renamed Earkick GmbH in Liquidation, with Stephan as liquidator.
  5. July 31, 2026: A 30-day call goes out for creditors to file claims.
  6. November 10, 2026: Elomia Health says it has acquired Earkick.

A solvent Swiss wind-up can be paperwork after a sale, and the companies did not describe distress. The sequence still matters. The legal vehicle in Wädenswil was already in liquidation while the public story was a live companion with more than 250,000 people on it. Stephan appears in both roles: COO in the deal quotes, liquidator on the Swiss file.

Mia21 Keeps Memory When Models Switch

Mia21 is the piece Pohrebniak described as understanding a person’s state and context over time. The Earkick team also sold it on its own as a gateway that remembers your users, an OpenAI-compatible pipe for GPT, Claude, Gemini and other models, with voice on the same key, prepaid from $5 and no markup on model tokens. The pitch on the product page is blunt: switch the model, keep the memory.

Bay’s public notes on the engine describe a consolidation pass before a new fact is stored. The system pulls facts from the user’s own words, sorts them (stable identity, relationships, preferences as long-term), then compares each new fact with what is already saved. Close matches are labelled add, skip or update so the file does not keep two versions of the same life. A second layer retrieves summaries of past chats, so the bot has both a profile and a history. Users, in that design, should be able to see, edit and delete what is remembered.

The deal does not say Elomia now owns Mia21 outright. It says the buyer gets ongoing early access to new versions, then will pair that engine with Elomia’s own models. On February 26, 2024, Pohrebniak wrote that simply remembering a name or a few incidents is useful in therapy but not the main job. A retrieval system trained on the right material, he said, should recall symptoms, emotions from earlier sessions, and a user’s beliefs about the world. That is the gap a longitudinal engine is meant to fill when a hospital or campus wraps a generic model and calls it care.

What the Penn Trial Tested

Elomia says independent studies have looked at its technology, including a recent randomised trial with the University of Pennsylvania. The public registry record for that work is NCT06725147, a 63-person college wellness trial run by Melissa Hunt, PhD. It is completed. Results are not posted.

THE PENN PROTOCOL ON FILE

  • Who enrolled: 63 University of Pennsylvania undergraduates, 18 or older, in an open-label crossover study.
  • When it ran: January 15, 2025 to May 30, 2025, with primary measures at baseline and a 4-week follow-up.
  • What it compared: Elomia, used at least once a week for about 30 minutes, against a static set of Penn digital wellness pages with no chat.
  • What it scored: Beck Depression Inventory (0 to 63), GAD-7 anxiety (0 to 21), and the Perceived Stress Scale.
  • Who was kept out: People with severe depression or suicidality, including a BDI score of 30 or higher or a 2 or 3 on the inventory’s suicide item.

The protocol describes Elomia as a generative program trained on replies from therapists skilled in cognitive-behavioral work, aimed at stress, anxiety, procrastination and feeling overwhelmed, with calming, sleep, grounding, breathing and self-esteem exercises. It also says the bot is not a substitute for professional care and should flag when a person needs more than a chatbot. Hunt’s file is a small campus study that excluded the sickest students and has not yet published outcomes. That is the evidence sitting behind a product now being offered as safe, compliance-ready support for clinics.

Hospitals and Campuses Are the Paying Users

On September 27, 2024, Google’s Ukraine Support Fund named Elomia Health among 24 startups in a $10 million round of equity-free awards, each up to $100,000, with eligibility for up to $350,000 in Cloud credits. Google’s own line then called Elomia a chatbot for people who cannot reach ordinary care because of cost or stigma. Two years later the same company is selling the pipe to the institutions those people would otherwise walk into.

WHO THE API IS FOR

  • Healthcare providers: Clinics and care groups that want a branded wellbeing chatbot without building the model stack.
  • Employers: Workplace programmes that want check-ins and pattern tracking inside existing benefits.
  • Universities: Campus wellness teams, the same setting as the Penn protocol.
  • Other care groups: Any organisation Elomia classes as care-focused and able to meet its safety bar.

That list is why a consumer companion with a habit log is useful even if the brand never grows. Hospitals do not buy a venting app. They buy something people will open, something that still knows last week’s sleep and mood, and something they can defend to a compliance officer. Earkick spent years on the first two. Elomia is packaging the third.

Pohrebniak Wants Less Dependence on the Bot

Elomia’s add-on in the combined stack is the layer that is supposed to stop people leaning too hard on a chatbot. Pohrebniak has made that the company’s line to institutional buyers: launch the bot so it is safe by design, and so staff and students actually use it.

The Earkick team spent years building an engine that understands a person’s state and context over time. By pairing it with our own models and our safety and overreliance-prevention layer, we’re making it a core part of our technology.

Taras Pohrebniak, founder and CEO of Elomia Health

Overreliance is the live risk in this category. A bot that remembers your week can feel like a friend, which is also how it becomes the only place a lonely student talks. Elomia’s pitch to a hospital is that the same memory which makes the bot usable can be wrapped in brakes: escalation when the BDI-style danger signs show up, and design that pushes a person back toward human care. The Penn protocol already wrote that rule in for students. The API deal is an attempt to sell that rule as a product.

The Consumer App Now Feeds Someone Else’s Software

The public conversation around the sale was thin, which is what a tuck-in for hospital software looks like from outside. Nobody had to argue about a consumer brand, because the brand is no longer the point. More than 250,000 people already taught the companion how daily venting looks. Mia21 is the file that is supposed to keep that context when the underlying model changes. Elomia’s trial record is a completed campus study with no posted scores. The Swiss company is in liquidation, and the US-facing product is now described as inventory for someone else’s chatbot.

Bay still talks about making wellbeing measurable. Pohrebniak still talks about organisations launching bots people will use. In between those lines sits a quieter transfer: a companion that used to be the product is becoming the memory and proof sitting under a hospital API, and the people who typed into it were never the customer Elomia is pitching next.

Disclaimer: This article is news reporting on a company acquisition and related public records. It is informational only and is not medical, mental-health or investment advice, and it is not a review of any chatbot as treatment. Do not use an app or API in place of care from a licensed clinician, and do not treat deal claims, trial protocols or product pages as a recommendation to buy, sell or use these tools. Speak with a qualified mental-health professional, and with a licensed financial adviser if you are weighing any related investment, before you act. User counts, trial statuses, register filings and product terms reflect the sources dated in the piece and can change.

Harry is the editor of IAQABA, an independent publication he owns and runs. A decade in journalism, beginning as a reporter and now as the editor of his own titles, has left him with a clear test for what deserves a story: it has to change what a reader knows or decides, and it has to rest on something he can point to. That rules out recycled press releases, forecasts with no data behind them and rumours that no document supports. It leaves room for a great deal, and the site covers news, business, science and technology alongside sports, entertainment and lifestyle, with travel, auto and gaming given the same standard rather than lighter treatment. Sources are primary wherever possible: the regulator's filing, the company's own statement, the transcript, the dataset, or the product on Harry's desk. Figures are checked before they are published and rechecked if a reader questions them. Mistakes are corrected under a published policy. Readers across the world can reach him directly at support@iaqaba.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending